At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 27 enrolled
Drug / intervention
Diphenhydramine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
In Brief
A Phase 3 clinical trial evaluating Diphenhydramine, Cetirizine, and 2 other interventions for Breast Cancer and 6 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the parameters necessary for the preparation, modification or even abandonment of the final study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Lung Cancer, Ovarian Cancer, Oesophageal Cancer, Head Cancer Neck, Cervical Cancer, Endometrial Cancer
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionAug 2020
Study CompletionSep 2020
TodayJul 2026
First PostedJan 22, 2020
Enrollment StartFeb 14, 2020
Primary CompletionAug 28, 2020
Study CompletionSep 4, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago
Interventions
Diphenhydraminedrug
Drug identification number : 02369567
Cetirizinedrug
Drug identification number : 02231603
Lactose pilldrug
Natural product number : 00501190
Sodium chloride 0.9%drug
Drug identification number : 00037796